Theravalues Corporation, Tokyo based company, will launch Theracurmin® Super for the European market at Hi Europe 2014, an event which will take place in Amsterdam at the beggining of December. 

Curcumin is a turmeric derivative, which is the pigment that gives its yellow-orange color to curry. It is a compound that has been the subject of many studies, and whose health effects are multiple. The consequence is that turmeric is becoming increasingly popular as a dietary supplement and 100 grams of turmeric contain 3 to 5 grams of curcumin.

Chinese and Indian traditional medicines exploit the therapeutic properties of it for thousands of years. It is known for its powerful anti-inflammatory, antioxydant, anticancer, antiviral and antibacterial activities. Moreover, it has been shown that curcumin influences the expression of over 700 genes, which may explain its health benefits. Despite its range of reported pharmacological effects, curcumin is limited in its clinical applicability by its low bioavailability during oral administration.

ADVERTISEMENT

Theravalues Corporation found the highest ever bioavailable curcumin, with a combination of amorphous (non-crystal) technology and ingredients approved by European regulations. The current curcumin product from Theravalues, Theracurmin®, proved 27 times higher bioavailability than ordinary curcumin powder. It has been studied in many human clinical trials over the world and obtained many significant positive results. For example, in heart failure, they obtained an improvement of diastolic dysfonction, they also had improved hepatic function.With this high bioavailability, Theracurmin® Super will make a huge contribution to treat and prevent a number of diseases in many countries, where aging populations rapidly grow.

Theravalues will expose their product at the Hi Europe event in Amsterdam. It is organized only once every two years and it is the premier live event dedicated to professional development in the functional foods, nutraceuticals, natural ingredients and nutritional supplements industries. 

Previous post

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Next post

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.